09:00 AM EDT, 10/06/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Monday that the supplemental new drug application for Zoryve cream 0.05% for the topical treatment of skin disease atopic dermatitis in children aged two to five has received approval from the US Food and Drug Administration.

The company said the once-daily cream can be used for any duration anywhere on the body, and that the commercial product will be available by the end of this month.

Shares of Arcutis were up more than 2% in recent Monday premarket activity.